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Abstract
Concussion is the most common form of mild traumatic brain injury (mTBI). TBI
resolution is modulated by neuroinflammation, which is augmented by the infiltration of
innate immune cells from the circulation. Peripheral, myeloid immune cells not only invade
neural tissues but other organs as well causing local inflammation and tissue damage,
known as systemic inflammatory response syndrome. Here, I assessed the temporal and
anatomical nature of the neural and systemic cellular inflammatory response to repetitive,
mTBI in a 3-hit mouse model of concussion. The results showed significant microglial
activity, accumulation of peripheral myeloid cells and prominent axonal damage postinjury. The peripheral immune cells emerged through the brain microvasculature and
resided in the parenchyma, along the pia mater and within the ventricles. There was also
evidence of systemic inflammation in the lungs as well as in the cervical spinal cords of the
mTBI mice.
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Summary for Lay Audience
Traumatic brain injury (TBI) has emerged as a silent epidemic of increasing importance
and frequency as it has gained global recognition as a high-profile public health issue.
Concussion falls under the milder end of the TBI severity spectrum, accounting for 70-90%
of all brain injury cases. However, since most individuals survive the initial trauma and do
not seek medical treatment, the total number of concussion is greatly underreported. As
there are many causes of TBI, injuries pertaining to the brain are often known as “the most
complicated disease of the most complex organ in the human body.” Despite this increasing
awareness of concussion and the possibility of long-term impairments, effective means of
diagnosis, prognosis and treatment options fail to exist and remains as a major unmet
clinical need. Furthermore, not only single but repeated occurrences of head injuries
constitute mounting concerns, and emerging literature supports both pathological and
behavioral differences between a single injury and multiple injuries. This is particularly a
major concern in the context of sports or military activities where these individuals are
subjected to multiple insults. There is evidence to suggest that immediately following a
head trauma, a period of vulnerability window exists and if a second concussion was
sustained within that period, a significant and even fatal damage can occur, known as
second impact syndrome. Prognosis and effective management guidelines are difficult
especially when social pressures exist for individuals to return to play or combat duties.
Moreover, there is a high level of uncertainty regarding the threshold for diagnosis, the
recovery trajectory and the predicted outcome. Here, I assessed the temporal and
anatomical nature of the brain and systemic cellular inflammatory response to repetitive
TBI in a 3-hit mouse model of concussion. The results showed significant activity of certain
immune cells in the brain called microglia and an accumulation of other types of immune
cells in the brain as well as in other organs. Overall, this study characterizes the
inflammatory responses following repeated concussive injuries in a mouse model to
establish its suitability for testing future therapeutics for clinical translation.
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CHAPTER 1 – INTRODUCTION
1.1 Overview
Traumatic brain injury (TBI) has emerged as a silent epidemic of increasing
importance and frequency as it has gained global recognition as a high-profile, public health
issue. Concussion falls under the mild end of the TBI severity spectrum, accounting for 7090% of all brain injury cases (1, 2) out of 2.5–3.8 million TBI cases per year in the United
States (3). However, since most individuals survive the initial trauma and do not seek
medical treatment, the total incidence of concussion is greatly underreported (4). As a
disease of multiple etiologies, injuries pertaining to the brain are often known as “the most
complicated disease of the most complex organ in the human body” (5). Despite the
increasing awareness of concussion and the possibility of long-term impairments, effective
means of diagnosis, prognosis and treatment options fail to exist and remain as a major
unmet clinical need (6, 7). Furthermore, not only single but repeated occurrences of head
injuries constitute mounting concerns, and emerging literature supports both pathological
and behavioral differences between a single injury and multiple injuries (8, 9). This is
particularly a major concern in the context of sports or military activities where patients are
subjected to multiple insults. There is evidence to suggest that immediately following a
head trauma, a window of increased neural vulnerability exists during which a second
concussion could result in a significant and even fatal brain injury. This is known as second
impact syndrome (10-12). Prognosis and effective management guidelines are difficult
especially when social and workplace pressures exist for individuals to return to play, work
or combat duties (13). Moreover, there is a high level of uncertainty regarding the threshold
for diagnosis, the recovery trajectory, and the predicted outcome.
Overall, the clinical impact of TBI is not only highlighted by the incident rate but
also by the long-term health consequences reported by individuals who have survived their
injuries. Imprecise classification, methodological inconsistencies and some uncertainty
about underlying pathophysiology hinder definitive methods of diagnosis and therapy for
concussions (14). Thus, this study aims to further characterize the pathogenesis of repeated
concussive injuries in an animal model in order to establish its suitability for testing future
therapeutics for clinical translation.
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1.2 Concussion
The majority of TBI cases (70-90%) are categorized as a mild injury within the TBI
severity spectrum (1). The term concussion has been popularized in the context of sports
medicine which is an injury known to exist under the umbrella of mild TBI (15). Commonly
found in literature, the word concussion and mTBI have been used synonymously. The
Quality Standards Subcommittee of the American Academy of Neurology defines
concussion as a transient neurological dysfunction induced by a biomechanical force
without gross lesions and structural abnormalities (16). An external force to the head and
neck region or a blow anywhere else in the body can produce a whiplash effect that is
transmitted to the brain. The acceleration/deceleration and rotational forces induce a change
in pressure and tissue strain that drives the pathological alterations associated with
concussion (17). It typically results in a rapid onset of acute neurological dysfunction and
the clinical symptoms of concussion reflect a functional disturbance induced by a
neurometabolic cascade of events (18). When a brain injury is suspected, it is classified
normally by the Glasgow Coma Scale (GCS) (19) ranging from mild, moderate to severe
in one spectrum (20). Dizziness, nausea, headaches, and amnesia are common symptoms
of mild to moderate TBI and usually resolves within days to weeks following the injury.
Occasionally, these symptoms can progress into long term consequences leaving the patient
with cognitive or behavioral deficits. It has been found that moderate to severe TBI and
even multiple mTBI are associated with an elevated risk of certain neurodegenerative
diseases including Alzheimer’s disease (21), chronic traumatic encephalopathy (CTE) (22)
and Parkinson’s disease (23). Specifically, NFL football players, long-term career boxers
as well as military personnel have been described to have some cognitive impairments (24),
neuroimaging abnormalities (25) and altered brain metabolism (26), disproportionate to
their age. This highlights the importance of understanding not only the impact of a single
concussion but also repeated injuries as well. It is now understood that at some undefined
point, concussion stops being a recoverable injury and accelerates to a chronic
neurodegenerative disorder.

1.3 Concussion pathophysiology theories
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Despite all the recent research in concussion, there is still a lack of consensus on
the pathophysiology which has led to an inconclusive pathological definition of concussion
and thereby no effective clinical treatment (15). Many concussion researchers state that the
literature is vast and that it may not be possible to simplify concussion into one
neuropathological explanation (27). As there are many etiologies of concussion, there exist
a plethora of theories for concussion pathophysiology (27). Concussions, like all other
forms of TBI, have a dynamic and biphasic injury progression that evolves over time. The
primary phase is the mechanical damage to the central nervous system (CNS) caused by
the application of acceleration/deceleration and rotational forces. More importantly,
regarding clinical aspects, secondary injuries arise from the complex network of vascular,
cellular and biochemical cascades that lead to further damage and exacerbation of longterm neurological symptoms (28-30).
Older theories of concussion pathophysiology describe that immediately following
a biomechanical injury, there is an abrupt disturbance in the electrochemical gradient and
an indiscriminate release of glutamate (31, 32), a prominent excitatory neurotransmitter.
The injury increases the permeability of the membrane to various ions that lead to a large
influx of sodium ions (Na+) and calcium ions (Ca2+) and the efflux of potassium ions (K+)
(31, 32). The rapid shift in ionic balances depolarizes the neuronal membrane and the result
is a massive release of glutamate (18). The excessive extracellular glutamate leads to
glutamate excitotoxicity via activation of neuronal glutamate receptors such as N-methylD-aspartate (NMDA) receptor. Sudden excitation of the brain is followed by a wave of
neuronal suppression called “spreading depression” (33). It is thought that loss of
consciousness, amnesia and other cognitive dysfunction following a concussive impact is
a manifestation of the post-traumatic spreading depression-like state. To restore the axonal
membrane potential, the sodium-potassium pump is overworked, causing hyper-glycolysis
and quick depletion of intracellular energy reserves (18). This state of hyper-metabolism
leads to a disparity between glucose supply and demand which can result in an “energy
crisis” (18). The effects of accelerated glucose consumption can be seen by the
accumulation of lactate production and decreased cerebral blood flow, worsening the
energy crisis (18). Elevated lactate levels, reduction in oxygen and glucose supply to
hypermetabolic neurons further drives neuronal dysfunction and axonal damage. The latter
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is referred to as diffuse axonal injury (DAI) (18). Shown by experimental animal studies
using various TBI models, there is no question that TBI induces a multitude of cellular and
molecular changes within the brain. However, it is problematic when these alterations do
not necessarily manifest into clinical symptoms. Studies have seen depressed cerebral
glucose metabolism after the initial period of hyperglycolysis in patients who presented
with no clinical symptoms (34). Clearly, significant neurometabolic abnormalities can
occur without any clear symptomatic indications. It is suggested that it takes 30 to 45 days
for the physiological parameters to resolve, which is well beyond when symptoms usually
settle (35). Much of the pathobiology of concussion has been elucidated through animal
models of TBI, but, further validation of these mechanisms need to be established in
humans.
As concussions are a common occurrence in sports, more recent studies in the
literature have described 5 predominant theories of pathophysiology specifically for sportsrelated concussions: 1) tauopathy 2) white matter tract changes 3) changes in neuronal
activity 4) reduced cerebral perfusion and 5) gray matter atrophy (27). 1) The tauopathy
theory is described as the abnormal elevation of phosphorylated tau protein in the cortical
sulci of the brain (36). Tau proteins are normally found in the brain, function to stabilize
microtubules in axons and are essential for neuronal communication. Hyperphosphorylated
tau leads to the accumulation of neurofibrillary tangles that affect neuronal network
connectivity that can result in cell dysfunction and cell death (37). 2) The theory that
involves the white matter tract changes is based on the degeneration of myelin, a lipid-rich
insulator surrounding axons that is responsible for efficient transmission of electrical
signals along neurons (38). Some examples of white matter tract changes include widening
of frontal and occipital sulci, the release of neuronal protein into the damaged brain and
DAI (39). 3) The neuronal connectivity theory indicates a reduction in global neuronal
networks occur that lead to less efficient coordinated communication between different
brain regions (40). 4) The cerebral perfusion theory is centered on the change in blood flow
arising following trauma that potentially leads to ischemia (41). 5) Lastly, a less common
theory proposes that concussion symptoms arise from trauma due to an overall shrinking
of cortical and subcortical structures including the thalamus and hippocampus (42).
Although many theories of concussion have been shared amongst TBI researchers, there is
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still ongoing debate and new theories are constantly being generated. It is no surprise that
concussion is caused by both structural and functional damage (43) that are heterogeneous
and multifactorial.

1.4 Repetitive concussion
While patients typically recover from a single incidence of concussion, cumulative
effects of multiple head injuries pose a more serious problem. Particularly in athletes and
military personnel, repetitive concussions are a common occurrence. Studies have shown
that repetitive concussions that occur during a period of increased neural vulnerability can
result in severe outcomes (12, 44). Clinical evidence of these severe outcomes is seen in
athletes who have sustained multiple traumas as evidenced by poor performance in
neurocognitive tests and demonstrating slower processing speed (45). Additionally, the
extent to which these athletes show neurocognitive dysfunction is attributed to the length
of time between sustained injuries. Clinical and experimental data have shown that
repetitive injuries with shorter durations between consecutive insults result in a markedly
greater cognitive, histological and behavioral impairments compared to injuries separated
by a longer period (46, 47). As mentioned previously, research has shown the potential for
multiple mTBI producing cumulative effects leading to long-lasting neurological
impairment including age and non-age related neurodegenerative disorders (CTE,
Alzheimer’s disease, Parkinson’s disease). Due to the high prevalence of concussions, it is
becoming increasingly important to uncover the underlying secondary injury mechanisms
that can explain brain sensitization to subsequent neurotraumas.

1.5 Neuroinflammation
The term neuroinflammation is used to describe the robust and complex
inflammatory response generated by the interaction between the cellular and soluble
components of the CNS and the periphery (48). Inflammation is a biological response to
tissue injury that is both necessary and beneficial because it promotes the clearance of dead
cells and debris and starts the process of tissue repair. However, too much inflammation
for an extended period of time is detrimental to the surrounding tissues and can progress to
chronic neurodegeneration (49-51). Immune targeting interventions for post-traumatic
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inflammation aims to limit acute inflammation just enough to promote regeneration and
prevent the development of chronic neuroinflammation. The mechanical damage of the
primary injury during a TBI induces the release of self-derived warning signals called
damage-associated molecular patterns (DAMPs) (52). DAMPs are endogenous molecules
that are released from stressed or dying cells which can include host proteins, nucleic acids
and metabolites (53) and they are sensed by pattern recognition receptors (PRRs). Upon
binding of DAMPs to PRRs, an inflammatory response is generated and amplified such
that pro-inflammatory mediators are released from all brain cell types and neural leukocytes
(perivascular and meningeal macrophages). Although neurons, astrocytes, microglia,
oligodendroglia, and endothelial cells are all capable of producing pro-inflammatory
cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-, the microglia
are the most critical immune cell in the first line of defense (54). Microglia are normally
quiescent, anti-inflammatory and charged with maintaining neuro-homeostasis (55).
However, activation of microglia lead to excessive amounts of pro-inflammatory cytokines
being released that can exacerbate the initial trauma, and hinder both brain repair and
functional recovery (54) while decreasing the levels of anti-inflammatory cytokines (IL-4,
IL-10 transforming growth factor (TGF)-). Anti-inflammatory cytokines are important for
counteracting and downregulating the inflammatory and cytotoxic reactions (56). TBI also
compromises the blood brain barrier (BBB)- a physical barrier separating the brain
parenchyma from cellular and soluble blood components (57). Breaching of this barrier
allows infiltration of peripheral immune cells into the parenchyma to exacerbate the
inflammatory response (58). A compromised BBB allows extravasation of not only cells,
but also plasma proteins into the brain. An example of such plasma protein is fibrinogen, a
plasma adhesion protein. Accumulation of fibrinogen induces neuroinflammation and
astrocyte scar formation by initiating TGF- signalling pathway (59). Although primary
injury occurs in a matter of seconds with a neuroinflammatory cascade commencing
thereafter, a prolonged state of inflammation after the injury can linger for many years and
predispose the patient to other neurodegenerative diseases (60). Chronic microglial
activation, alterations in neuronal activity, reduced dendritic spine density in post-TBI
patients all occur in parallel with long-lasting inflammatory responses (61). It is becoming
increasingly clear that persistent neuroinflammation is associated with an elevated risk of
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developing progressive life-long impairments in a patient’s physical, cognitive, behavioral
and social performance (49, 50). However, the initial inflammation also sets the stage for
neural regeneration and recovery (62). Inflammation is referred to as a “double-edged
sword” with both ameliorating and deleterious effects. This could explain why immunesuppressing drugs administered immediately post-TBI in human clinical trials have failed
(63). Targeted therapeutic interventions are required to balance the benefits of the initial
inflammatory response to promote neuro-regeneration and restoration of normal brain
function while preventing detrimental, chronic inflammation that further undermines
neurocognitive function.

1.6 Microglia
Microglial activation is a key hallmark of TBI. As the brain’s resident, parenchymal
macrophages, it’s important to understand their normal functions during homeostasis,
diseases and traumas inflicted on the CNS. It has been over a century since the discovery
of microglia as the “third element” of the CNS (64). After much debate on the origin of
microglia, it has only been recently shown that microglia arise from embryonic yolk sac
(YS) precursors, which also gives rise to some tissue macrophages (65-67). This means
that microglia and tissue resident macrophages are developmentally and functionally
different from blood derived myeloid lineage cells (68). The previous notion that microglia
are a static bystander in the healthy CNS that have minimal functions besides scavenging
and immune surveillance has also been proved to be a misconception (68). In fact,
microglia interact with all components of the CNS, constantly monitoring the brain
microenvironment by extending their processes and maintaining tissue integrity (69, 70).
Early in development during embryogenesis, the YS myeloid precursors travel to the brain
before developing into immature microglia. Thus, microglia participate and interact with
the development of other CNS cells including neurons, astrocytes and oligodendrocytes
(71). It is not surprising that microglia activation is a key hallmark of almost all diseases
and injuries related to the CNS (72, 73). While quiescent microglia have a ramified
morphology, activated microglia are characterized by a hypertrophied, “bushy” and
“amoeboid” phenotype (74). In a repetitive concussion rat model, microglial morphological
change was clearly noticeable in the sub-cortical white matter, the cortex and the
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hippocampus (75). Within hours after a TBI, the microglia adopted a pro-inflammatory,
“classically activated” M-1 phenotype (75) exemplified by a significant upregulation of
many M-1 markers including CD86, iNOS, MHC II, Nos2, IL-1, CCL2, CXCL1(76).
Only a few M-2 “alternatively activated” markers such as Arg-1, TGF-, CCL22 and Lif
(76) were upregulated, indicating that pro-inflammatory M-1 phenotype dominated in the
early hours after concussive injury (75). However, other transcriptome analyses of
microglia revealed that these states are transitory and during the chronic stage of microglial
activation includes a mixed expression of both M-1 and M-2 phenotypic markers (55). The
acute function of activated microglia following TBI is to migrate to the site of lesion,
phagocytose cellular debris, re-establish a neuroprotective environment by orchestrating
neurorestorative processes (54). However, microglia are also capable of producing
inflammatory mediators such as reactive oxygen and nitrogen species, neurotransmitter
glutamate and inflammatory cytokines (77). Depending on the amount released, glutamate
can directly cause neurotoxic effects in neurons, synapses and astrocytic functions by
hindering the glutamate buffering ability of astrocytes and blocking their glutamate
transporters (78).
Microglial cells are commonly identified by their ionized calcium-binding adaptor
molecule 1 (Iba-1), also referred to as allograft inflammatory factor 1 (AIF-1). This
molecule is an actin binding protein involved in membrane ruffling and phagocytosis (79).
This marker has been widely accepted to identify microglia, as well as tissue-resident
macrophages and monocyte-derived macrophages but is not expressed by circulating or
infiltrating monocytes (80).

1.7 Neutrophils
As the most abundant leukocyte in peripheral circulation and the earliest to arrive
at the site of injury, neutrophils come armed with an array of antimicrobial effector
molecules (81). Many human and animal studies have shown that following TBI, profound
neutrophilia is found in the bloodstream both in absolute number (82-84) as well as in
frequency (82, 84). Neutrophils are polymorphonuclear cells, generated and matured in the
bone marrow from a myeloid precursor (85). They are located in the bone marrow, spleen,
lungs, liver and in circulation, but rarely found in the brain parenchyma due to the BBB
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(86). They become activated and/or differentiate into more mature effector cells depending
on the environmental stimuli. Endogenous factors such as granulocyte-colony stimulating
factor (G-CSF) and granulocyte-macrophage-colony stimulating factor (GM-CSF) (87) as
well as external stimuli induced by stress or trauma (88) lead to the upregulation of different
membrane receptors and expression of various granule proteins essential for degranulation
and become phagocytic (89). Additionally, the list of neutrophil-derived cytokines is
extensive (90, 91). Tumor necrosis factor (TNF) family; pro-inflammatory cytokines;
CXC-

chemokines;

CC-

chemokines

as

well

as

other

anti-inflammatory,

immunoregulatory, angiogenic and neurotrophic factors were all associated with TBIinduced cytokine release from neutrophils (92-97). Recruitment of neutrophils into the
brain parenchyma and hence, their activation is associated with different characteristics of
TBI. Hypoperfusion, seen in moderate to severe TBI cases enhances the interactions of
neutrophils with blood vessels (98) increasing neutrophil adherence to endothelial cells
(99). Neutrophil-derived neutrophil elastase (NE) (100, 101) and matrix metalloproteinase
(MMP) also play a role in BBB dysfunction (102, 103). Free radicals generated by
neutrophils also cause direct oxidative damage interfering with the BBB integrity (104).

1.8 Monocytes/Macrophages
Monocytes are crucial immune cells responsible for initiating innate immune
responses (105). These myeloid-derived cells originate from the bone marrow and reside
in peripheral blood and spleen until they are trafficked to the site of tissue injury.
Monocytes are a heterogeneous population of inflammatory cells, making up 5-10% of
leukocytes in the circulation. There are 3 subclasses of monocytes in humans, differentiated
by their surface expression of CD14 and CD16: classical (CD14++16–), non-classical
(CD14lo/+16++), and intermediate (CD14++16lo/+) (106). The role of each cell type has been
studied extensively in infectious diseases, however, the importance of these cells in sterile
injury is only just being elucidated. In a trauma-induced inflammatory cascade, classical
monocytes are recruited out from the bone marrow and into the blood stream (105). Human
studies have reported a significant elevation in the absolute number of circulating
monocytes (83, 84) while murine models have shown a reduction in monocyte numbers in
the early hours and days post-TBI (107). In mice, monocyte subtypes are classified into
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classical (Ly6C+) and non-classical (Ly6C-), each with a unique phenotype and function.
The classical monocytes have been described as inflammatory migrating cells that are
recruited from the bone marrow to the inflamed tissues to produce TNFα and IL-1β. The
chemokine, monocyte chemoattractant protein-1 (CCL2) is largely responsible for this
monocyte chemotaxis along with its receptor, CCR2 (108). CCL2 is not only important for
monocyte mobilization but it also promotes adhesion onto the endothelial vessel wall (109).
Shown in a rat model of TBI, the epithelial cells of choroid plexus secreted CCL2 which
encouraged monocyte migration across the blood-cerebrospinal fluid barrier (110). Once
in the tissues, the classical monocytes differentiated into macrophages or dendritic cells
(111). The non-classical monocytes arise from the classical monocytes with downregulated
expression of Ly6C and are situated along blood vessel walls with the role of “patrolling”
the vasculature (111). Thus, under conditions of injury and inflammation, non-classical
monocytes rapidly extravasate into the tissues and participate as one of the first responders
(112). Within the tissues, the non-classical monocytes convert into more specialized
phagocytic cells such as CD11c+ MHC II+ dendritic cells and MHC II+ macrophages (111).
In a closed-head mouse model of TBI, while classical monocyte frequency is
downregulated, the non-classical monocytes increase in circulation 60 days post-injury,
suggesting that TBI shifts into an anti-inflammatory state (107). In parallel, when
monocytes were isolated from TBI patients at that time post-TBI, IL-10 expression was
upregulated, indicating an anti-inflammatory response in circulating monocytes (113).
While monocytes are in circulation, macrophages reside in tissues and have more
of an M-2 phenotype to maintain tissue homeostasis. In disease pathology, the influx of
pro-inflammatory monocytes at the site of injury outnumber the tissue-resident
macrophages and differentiate into classically activated macrophages. Particularly in
chronic inflammatory conditions and tissue degradation, macrophages stay activated,
suppress their tissue-repair functions and delay wound-healing processes (114). Both
monocytes and macrophages are not only implicated in TBI, but they also play a role in
spinal cord injury, ischemic stroke injury, cardiovascular diseases as well as hepatic injury
(114).

1.9 Systemic inflammatory response syndrome
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It has been established in the literature that trauma evokes a systemic immune
reaction that can often be more fatal than the initial primary injury itself (115). This acute,
nonspecific immune response results in damage to organs by the cascade of inflammatory
events that subsequently lead to sepsis which the individual is susceptible to (115).
Collectively, this is called systemic inflammatory response syndrome (SIRS). Particularly
following a severe injury such as severe TBI or spinal cord injury, the initial inflammatory
cascade elicits the release of endogenous factors, DAMPs and alarmins that bind and
activate innate immune cells via PRRs (116). Alarmins are defined as self-molecules that
are released during non-programed cell death, by some immune cells and have the ability
to initiate homeostasis and repair mechanism (53). DAMPs also activate the complement
system, generating C3a and C5a (117, 118) further contributing to the pro-inflammatory
milieu. Subsequently, pro-inflammatory mediators are rapidly generated and released into
the damaged area and further contribute to an inflammatory state. Additionally, the
increased pro-inflammatory cytokines also reduce the integrity of the blood brain barrier,
allowing increased permeability. This not only permits the entry of peripheral cells and
molecules to enter the CNS but the lesion-generated inflammatory mediators, DAMPs,
cytokines and acute phase reactant mediators can now pass into the systemic circulation.
Particularly, neutrophils have been shown to actively participate in migration to,
sequestering in and damaging “by-stander” organs (119). Acute respiratory distress
syndrome (ARDS) is a well-recognized complication in TBI patients and is a primary
example of organ damage caused by a brain injury-driven systemic inflammatory
responses. Neutrophils are known to migrate into the alveoli (120) and release toxic
mediators including proteases and reactive oxygen species that normally function to kill
pathogens but in the case of ARDS, also cause damage to healthy tissue. Alveolar edema
and arterial hypoxaemia (121) occur as a result of increased lung epithelial and endothelial
permeability (122). Importantly, although neutrophils are implicated in the acute
development of SIRS, their functions are markedly decreased the following days after TBI
(123).
Understanding of the mechanisms that mediate central regulation of immune
functions through the autonomic nervous system has been a major development in the field
of neuroimmunology (124). The discovery of the vagal nerve stimulation causing
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attenuation of the systemic inflammatory response is an important concept related to TBI.
Under inflammatory conditions, the brain sends signals via the vagus nerve to attenuate
inflammatory cytokine production as a brain protective mechanism (125). The vagus nerve
is the 10th cranial nerve of the CNS, as a part of the parasympathetic nervous system,
regulating critical organ functions necessary for survival. While 80% of the vagal nerve are
sensory fibres, gathering information from the heart, liver, spleen and gastrointestinal tract,
it also has the ability to sense and respond to peripheral inflammatory process through
efferent fibres (125). Collectively, the efferent and afferent sensory fibers participate in a
this mechanism known as the inflammatory reflex (126). The “Cholinergic antiinflammatory pathway” has been termed to describe the regulatory activity of the vagus
nerve carrying signals to resident macrophages via their primary neurotransmitter,
acetylcholine (ACh) to modulate local and systemic inflammation (125, 127). Upon
ligation of ACh to 7 nicotinic acetylcholine receptor on macrophages and dendritic cells,
the major pro-inflammatory cytokine TNF’s release was attenuated (127, 128). Thus, in
TBI, this inflammatory reflex can become disrupted contributing to cytokine dysregulation
and exacerbating the overall inflammatory response (125). Given the implication of
inflammation in numerous diseases processes, the cholinergic anti-inflammatory
mechanisms are being investigated for translational studies in animal models to humans.

1.10 Mouse models of TBI
Human TBI is challenging to study due to a large amount of heterogeneity in patient
and injury characteristics with a wide variety of patient outcomes. To characterize such
complex pathogenesis, no one pre-clinical animal model can capture the full breadth of
TBI, thus many animal models have been developed and modified to enable systemic
exploration of the concussion pathophysiology. Out of the various existing models of TBI
that can be applied, the following four models have been shown to be well-suited for
replicating concussive injuries; 1) fluid percussion injury (FPI), 2) Marmarou weight drop
(WD) model, 3) the closed-head impact model of engineered rotational acceleration model
(CHIMERA), and 4) the controlled cortical impact (CCI) (129).
FPI uses a hydraulic pressure pulse onto the exposed dura of the brain following a
craniotomy. The pulse is generated when a pendulum strikes a fluid-filled piston. Mild,
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moderate or severe injury can be achieved by adjusting the intensity of the pressure and
this model has been used on a number of animals including mice, rats, cats and pigs to
generate a diffuse brain injury that has corresponding pathological and neurobehavioral
changes (130-132). Brain contusions are clearly visible in this model, along with
pronounced microglial activation and astrocytosis (133, 134) while cerebral hypoxia, death
and apnea are common complications from FPI due to brainstem trauma (135, 136). The
weight drop model involves a mass that is dropped from a certain height onto a metal plate
that is attached to the skull of an animal. The metal plate prevents the skull from fracturing
while allowing the head to accelerate during the impact causing DAI, axonopathy,
neuromotor and cognitive deficits (137-139). CHIMERA is a newer variation of closed
head injury model that enables traumatic flexion of the cervical spine and additional
rotational acceleration of the head causing a whiplash effect. The neuropathological
consequences seen in this model are DAI, reactive microgliosis, the release of
inflammatory cytokines, and hyperphosphorylated tauopathy (140). CCI also delivers a
direct impact to the intact dura through a craniotomy by using a pneumatic piston. The
depth, speed and duration of the impact can be adjusted according to each experiment. CCI
causes cortical tissue loss, disturbance of the BBB, neuroinflammation, axonopathy and
brain contusions (141-144). While this model enables a continuum of injury severity, it also
induces tissue necrosis in and around the impact depression area. Thus, an alternative
configuration of this model has been developed where the impact is made onto the skull
(extracranial CCI) to reflect more of a human concussion. Each animal model has its unique
strengths and limitations. One of the biggest weaknesses in all of these models is the
requirement of anesthesia during experimental neurotrauma (145). This is important to
consider because time-dependent changes in reflex responses latencies are commonly
employed for initial neurological assessment following concussions in humans. These
include corneal, papillary and pinna reflexes, which are metrics used to capture the
constellation of neurological signs and symptoms of concussion which are not translatable
in animal models (129). The impact of the anesthesia is compounded when these models
are used to create a repetitive TBI model requiring anesthesia to be applied each time the
animal is subjected to an experimental TBI. A common strength in these models is the
robust secondary injury that is elicited in all TBI models. Currently, it is evident that no
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one model encompasses all aspects of human concussion perfectly (146), and thus the
development of new animal models and extrapolation of findings from different models
need to be adopted. This study used the extracranial CCI, or a closed-head injury (CHI)
model as this model reliably delivers controlled impact to the skull of each animal that
allows for a consistently reproducible head injury that is reflective of a human concussion.

1.11 Lys-EGFP-ki transgenic mouse model
The Lys-EGFP-ki mice is a transgenic mouse model that expresses the enhanced
green fluorescent protein (EGFP) gene into the murine lysozyme (lys) M locus. Lysozyme
is highly expressed in myelomonocytic cells, thus, only mature, granulomyelomonocytic
cells will exclusively be EGFP positive (EGFP+) (147). This includes hematogenous
macrophages, monocytes and neutrophils. The advantage of using this mouse strain is that
it allows for the distinction between the hematogenous monocyte derived macrophages and
the microglia which do not express EGFP.

1.12 Purpose, goals and objectives
In this study, I assessed the temporal and anatomical nature of the neural and
systemic cellular inflammatory response to mTBI following repetitive concussive impacts
using the extracranial CCI model. As there remains a clear medical need to treat brain
injuries, there is a strong rationale supporting the need to understand and characterize TBIassociated inflammation within the CNS as well as in the periphery to identify targets for
pharmacological interventions. To accomplish this, it is essential to select a suitable animal
model for testing anti-inflammatory therapies post- TBI. This study can lay the foundation
for the early pre-clinical testing in a mouse model of TBI of anti-inflammatory
immunotherapies to limit secondary injury and promote regeneration. Advances in
understanding the central and peripheral inflammatory responses to TBI can open a new
frontier in ways we can manage and prevent the ramifications of concussion and other
forms of TBI.
Thus, I hypothesize that the repetitive, closed-head injury of mTBI using a mouse
model will initiate cellular inflammatory events in the brain and in the periphery manifested
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via infiltration of hematogenous leukocytes. This will result in greater mature myeloid cell
accumulation in the brain and in various organs, following the injury.

1.13 Specific aims
1) Qualitatively and quantitatively assess the spatial and temporal appearance of the
microglial and the hematogenous myeloid inflammatory cell response in the brain
after repetitive concussive impacts.
2) Quantitatively assess the systemic hematogenous myeloid cell response to
repetitive concussive impacts.
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CHAPTER 2 – MATERIALS AND METHODS

2.1 Animal ethics
In accordance with the Canadian Guide to Care and Use of Experimental Animals,
all animal procedures were approved by Animal Care Committee at Western University
(London, ON) and were performed according to the principles of the Guide for the Care
and Use of Laboratory Animals (AUP# 2016-019, Expiry date: 10/01/2020, Appendix 1).

2.2 Lys-EGFP-ki mice
C57BL/6, lysozyme-EGFP-knock in (lys-EGFP-ki) transgenic mice were originally
provided by Thomas Graf, from Albert Einstein College of Medicine (Bronx, NY).
Homozygous lys-EGFP-ki mice were bred in the barrier facility at the West Valley
Building, Western University. Animals were housed single-caged with a 12 h light/dark
cycle and free access to food and water at all times. This study involved a total of
approximately 80 animals (males and females combined) which were between 11-17 weeks
of age and between 17g-32g in weight.

2.3 Pre-operative treatment
Prior to experimental use, the animals were acclimated for 1 week in the pre- and
post-operative animal room. The experimental lys-EGFP-ki mice were anaesthetized using
4% isoflurane (Baxter Corporation, Mississauga, ON) in 2% oxygen, this was reduced and
maintained at 3.5% isoflurane once the surgery began. The toe pinch reflex was performed
to ensure the animals were anesthetized before the procedure commenced. The hair on the
back of the head and neck was sterilized with 75% ethanol followed by a midline incision
to peel back the skin and expose the skull.

2.4 Closed-head injury model
TBI was experimentally induced by a computer controlled Precision Systems
Instruments TBI device (Lintech, Monrovia, CA). The piston settings to achieve the mild
brain injury were the following: speed of 3.5m/s, depth of 1.5mm and dwell time of 500ms.
The actual recorded impact speed can be found in Table 1. The 4mm silicone tip was set to
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Table 1. The recorded velocity of the impactor shown in m/s

8hr
mouse 1

mouse 2

mouse 3

mouse 4

mouse 5

day 1
day 2
day 3
day 1
day 2
day 3
day 1
day 2
day 3
day 1
day 2
day 3
day 1
day 2
day 3

24hr
3.62
3.72
3.58
3.44
3.77
3.55
3.61
3.59
3.42
3.75
3.71
3.61
3.74
3.60
3.72

3.59
3.83
3.72
3.57
3.54
3.56
3.65
3.85
3.73
3.70
3.73
3.58
3.74
3.64
3.66

mTBI Cohorts
48hr
72hr
1w
2w
3.67
3.82
3.62
3.61
3.47
3.80
3.64
3.70
3.62
3.79
3.59
3.58
3.76
3.86
3.86
3.78
3.78
3.57
3.66
3.70
3.64
3.73
3.79
3.74
3.79
3.56
3.69
3.67
3.68
3.59
3.72
3.73
3.56
3.54
3.60
3.72
3.74
3.72
3.68
3.59
3.52
3.62
3.78
3.52
3.85
3.62
3.86
3.66
3.54
3.74
3.59
3.61
3.83
3.69
3.64
3.70
3.49
3.59
3.84
3.51
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impact the brain in the middle of the skull, on the bregma suture. Immediately following
the impact, the mice were injected with an analgesic, Buprenorphine (RB Pharmaceuticals
Ltd, Berkshire, UK; 0.05 mg/kg) after the injury. The incision was closed and sutured with
4-0 vicryl (Ethicon, USA) and the animals were placed under a heat lamp, in the dark for
recovery. A total of three impacts were made, 24h apart. A group of sham-injured mice
were also included in this study. Sham cohort received the same treatment as the injured
group without the delivery of the impacts.

2.5 Perfusion
The mice were euthanized at 8h, 24h, 48h, 72h, 1- and 2-weeks post-surgery to
evaluate the inflammatory response of circulating blood leukocytes to mTBI. Each time
point included 6-10 mice of equal male/female ratio. For euthanasia, each mouse received
a total of 50μL of ketamine (68 mg/mL) and xylazine (6.8 mg/mL) through intraperitoneal
injection). The cardiac puncture method was used to withdraw peripheral blood from the
right atrium of the heart after administration of 1μL of heparin (0.01 USP/mL).
Subsequently, the spleens were harvested and placed on ice until processing.
Immediately following the removal of the spleen, a 23G perfusion needle was
inserted into the left ventricle of the heart and the mice were perfused into the apex of the
heart with 100mL of RPMI 1640 medium (Gibco by Life Technologies, Dulbecco’s
Modified Eagle Medium), followed by 100mL of freshly prepared 4% paraformaldehyde
(PFA, polyoxymethylene, Bioshop Canada Inc., Burlington, ON) in phosphate-buffered
saline (PBS). On completion of the perfusion, the following organs were removed: brain,
cervical spinal cord, lungs, liver, kidneys, and heart. All organs were cryopreserved in 10%,
20% and 30% sucrose solutions for 24h each at 4 °C.

2.6 Cryosectioning
All organs were frozen and embedded in optimum cutting temperature compound
(OCT) (Sakura Finetek, USA, Torrance, CA) and cryosectioned using the Leica Cryostat
(Leica CM 1950). One lung and one lobe of the liver from each mouse were transversely
sectioned in 16m thickness. The cervical spinal cords were also cut in cross sections, in
16m thickness. The peripheral organ sections were mounted onto a series of 6 Superfrost
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plus-charged slides (Fisher Scientific, Pittsburgh, PA), with a distance of at least 96μm
between each section on a single slide.
The brains were coronally sectioned to generate 20m slices from the end of the
olfactory bulb all the way to the beginning of the cerebellum. The brain sections were
mounted in the same manner as described above for the organs, with a 120μm distance
between each consecutive section on the same slide. Once the section of the brain directly
underneath the bregma suture was identified and marked as 0mm, two consecutive sections
0.5mm and 1mm rostral to the bregma and two consecutive sections 0.5mm and 1mm
caudal to the bregma were identified (5 sections in total), see Fig. 1. These sections were
later co-stained for immunohistochemical analyses. All slides were stored at -20C.

2.7 Blood processing and staining for flow cytometry
The blood collected from each mouse was processed and stained with appropriate
antibodies to characterize the myeloid and lymphoid cell populations. 100μL of blood from
each mouse was aliquoted to individual fluorescence activated cell sorting (FACS) tubes
(Falcon, BD). All samples were incubated with LIVE/DEAD Fixable Aqua Dead Cell Stain
(Thermo Fisher Scientific) in the dark for 20min. Then, fluorescently-labelled antibodies
were added to the appropriate samples on ice for 20min. A comprehensive list of the
antibodies used for the myeloid panel can be found in Table 2 and the antibodies used for
the lymphoid panel can be found in Table 3. Anti-mouse CD19, NKp46, CD3 and CD45
(BioLegend Inc., San Diego, CA) antibodies were used for the lymphoid panel. Anti-mouse
CD11c, CD11b, CD45, Ly6G, Ly6C (BioLegend Inc.), CD115 (eBioscience Inc., San
Diego, CA) and F4/80 (BIO-RAD, Hercules, CA) antibodies were used for the myeloid
panel. All antibodies were incubated in a total cell suspension of 100 μL. Red blood cells
(RBC) were lysed with BD Pharm Lyse Lysing buffer (BD) for 12 min before being washed
with Hank’s Balanced Salt Solution (HBSS) (Thermo Fisher Scientific) +0.1% bovine
serum albumin (BSA) (EMD Millipore, Billerica, MA). Samples were then centrifuged at
4C for 5min at 500xg, the supernatant was poured off and the cells were washed again
with HBSS+0.1%BSA. All samples were resuspended in 200μL of HBSS+0.1%BSA and
100μL of 4% PFA. Finally, 50μL of CountBright Absolute Counting Beads (Thermo
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Figure 1. The five alternate brain sections selected for analysis. The number above each
brain image indicates the distance away from the bregma suture. 0mm section is the area
directly underneath the bregma. +1mm section is 1mm distance rostral to the bregma and 1mm section is 1mm distance caudal to the bregma. The images were obtained from ©1999
RW Williams, designed by AG Williams, Atlas by T Capra.
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Table 2. Antibodies used for the myeloid panel
Cell/Protein target

Antibody

Antibody
dilution

Flurophore

RRID

Source

Macrophage
Dendritic cell
Monocyte
Myeloid Lineage
Leukocyte
Neutrophil

F4/80
CD11c
CD115
CD11b
CD45
Ly6G

1:200
1:80
1:160
1:400
1:500
1:40

322048
2563655
2566460
493546
493715
2562567

BIO RAD
Bio Legend
Bio Legend
Bio Legend
Bio Legend
Bio Legend

Monocyte

Ly6C

1:200

2562630

Bio Legend

Dead cells

Live/Dead
Aqua Vital
Dye

1:200

PE
PE/Dazzle 594
PE-Cyanine7
Alexa 647
Alexa 700
Brilliant Violet
421
Brilliant Violet
711
N/A

N/A

Thermo
Fischer
Scientifc
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Table 3. Antibodies used for the lymphoid panel
Cell/Protein target

Antibody

Antibody
dilution

Flurophore

RRID

Source

T cell

CD3

1:40

11203705

Bio Legend

B cell
NK cell
Leukocyte
Dead cells

CD19
Nkp46
CD45
Live/Dead
Aqua Vital
Dye

1:1500
1:50
1:500
1:200

Brilliant
Violet
PE
APC
Alexa 700
N/A

313643
10612758
493715
N/A

Bio Legend
Bio Legend
Bio Legend
Thermo
Fischer
Scientific

24
Fischer Scientific) were added and the samples were stored in the dark at 4C. UltraComp
antibodies capture beads (eBioscience Inc.) were used for electronic compensation.

2.8 Spleen processing and staining for flow cytometry
The spleens collected from each mouse were minced and pushed through a 70μm
filter (Falcon, BD) into a 50mL falcon tube. Splenocytes were washed with 1x PBS and
spun at 4C for 5min at 500xg, the supernatant was poured off and the cells were
resuspended in 4mL of RPMI media. Cells were filtered again with a 40μm filter, washed
with 1x PBS and spun at 4C for 5min at 500xg, the supernatant was poured off and the
cells were resuspended in 5mL of ammonium chloride lysis buffer (Stemcell Technologies,
Vancouver, BC) for 7min to lyse RBC. Additional PBS was added to each sample before
the spin and discarding of the supernatants and resuspension in 1x PBS. The cell
suspensions were stained using the same protocol as for blood.

2.9 Flow cytometry
Blood cells and splenocytes were analyzed by an LSRII analytical flow cytometer
(BD). All samples were run for maximum event collection and the data was analyzed using
FlowJo Software version 10 (Tree Star Inc., Ashland, OR).

2.10 Iba-1 and EGFP co-staining for immunohistochemistry
To phenotype the EGFP cells and distinguish them from the microglial cells, the
sectioned brains were co-stained with anti-Iba-1 and anti-GFP specific antibodies. Iba-1 is
a calcium ion binding protein expressed on macrophages and microglia (79). On day 1, the
slides were extensively washed with PBS and blocked for 3h with 5% normal goat serum
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and 0.3% Triton X-100
(Bioshop, Burlington ON) for non-specific binding. The slides were then incubated with a
rabbit monoclonal anti-Iba-1 antibody (1:300) (Abcam, Cambridge, United Kingdom) at
4° C overnight in the dark. On Day 2, the slides were briefly washed with PBS before being
incubated with a secondary goat anti-rabbit IgG directly conjugated to Alexa 546 (1:500)
(Life technologies, Eugene, OR) at room temperature for 1h. Finally, the slides were stained
with Alexa 488 conjugated anti-GFP rabbit polyclonal antibody (1:1000) (Invitrogen,
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Carlsbad, CA) overnight at 4°C in the dark. On Day 3, the slides were washed and rinsed
in double distilled (DD) water before being air-dried and cover-slipped with hard set
mounting media containing DAPI (4,6-diamidino-2-phenylindole, Vector Laboratories,
Burlingame, CA). A comprehensive list of all antibodies used for immunohistochemistry
can be found in Table 4. The specificity of the Iba-1 antibody was confirmed by staining
one section with the Iba-1 primary antibody and one section without the primary antibody.
A representative image showing this specificity can be found in Appendix 2.

2.11 Ly-6G DAB staining for immunohistochemistry
DAB (3,3′-Diaminobenzidine) is a derivative of benzene and when oxidized by
hydrogen peroxide, a brown precipitate forms. To distinguish between the neutrophils and
the monocytes in the brain, DAB staining with Ly-6G antibody from the DAB peroxidase
substrate kit (Vector Laboratories, Inc., Burlingame, CA) was used. Neutrophils are
Ly6G+EGPF+ and monocytes are Ly6G-EGPF+. The slides were extensively washed with
PBS followed by quenching of endogenous peroxidases using 3% H2O2 solution (RW
Packaging Ltd., Winnipeg, MB) in PBS for 10 min at room temperature. Then, slides were
washed with PBS and the sections were blocked with 5% normal goat serum for 2h at room
temperature. Next, sections were blocked with fragment goat anti-mouse IgG (0.13mg/mL;
Sigma Life Science) in PBS for 2h at room temperature to reduce non-specific binding of
mouse IgG (Fc fragment specific). Then, the slides were incubated with biotin conjugated
anti-mouse Ly-6G (1:300; eBiocience Inc.) overnight at 4°C. The next day, slides were
washed with PBS, and incubated with secondary antibody horse radish peroxidase (HRP)
conjugated to streptavidin (1:500; Invitrogen) for 1h. Following 4 washes with DD water,
DAB solutions from the DAB peroxidase substrate kit were added for 7-10 min. The slides
were then rinsed with DD water and air-dried before being dehydrated and cover-slipped
with Cytoseal mounting media (Thermo Fisher Scientific).
Spleen and excitotoxin brain sections were provided by a previous Master student
in the Dekaban Lab, Oleksandr Prokopchuk, who used an excitotoxin-induced model of
TBI to study immune responses in the CNS.
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Table 4. Antibody used for immunohistochemistry
Cell/Protein target

Antibody

Antibody
Dilution

Flurophore

RRID

Source

Microglia &
Macrophage

Primary Rabbit
monoclonal
anti-Iba-1
Secondary goat
anti-rabbit
Rabbit antiGFP
rabbit
polyclonal antiCD31
Secondary goat
anti-rabbit IgG
fragmented
goat anti-mouse
IgG
biotin
conjugated
monoclonal
Anti-mouse Ly6G
secondary
antibody HRP
conjugated to
streptavidin

1:300

N/A

2636859

Abcam

1:500

Alexa 546

2534077

1:1000

Alexa 488

221477

Life
technologies
Invitrogen

1:300

N/A

726362

Abcam

1:300

Alexa 546

2534077

Invitrogen

0.13mg/mL

N/A

N/A

Sigma Life
Science

1:300

N/A

469757

eBioscience

1:500

N/A

N/A

Invitrogen

Microglia &
Macrophage
Monocyte/Macrophage
Neutrophils
Endothelial cells

Endothelial cells
Neutrophils

Neutrophils

Neutrophils
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2.12 CD31 and EGFP co-staining for immunohistochemistry
In order to evaluate whether EGFP+ cells enter the brain from the blood stream, the
brain sections were stained for CD31, a platelet endothelial cell adhesion molecule. On day
1, all slides were washed extensively with PBS and blocked with 5% normal goat serum
and 0.3% Triton X-100 for non-specific binding for 3h. The slides were then incubated
with the rabbit polyclonal anti-CD31 antibody (1:300; Abcam) at 4° C overnight in the
dark. On Day 2, the slides were briefly washed with PBS before being incubated with
secondary goat anti-rabbit IgG directly conjugated to Alexa 546 (1:300) at room
temperature for 1h. Finally, the slides were incubated with Alexa 488 conjugated anti-GFP
rabbit polyclonal antibody (1:1000) overnight at 4° C in the dark. On Day 3, the slides were
washed with PBS and rinsed in DD water before being air-dried and cover-slipped with
hard set mounting media containing DAPI.

2.13 Silver staining
To detect axonal damage in the concussed brains, 50m sections were cut on the
cryostat and preserved as floating sections in 4% PFA for 1 week. Using FD NeuroSilverTM
Kit II (FD NeuroTechnologies, Inc.), the exact protocol provided in the user manual was
followed. Upon completion, the floating sections were mounted on a superfrost pluscharged slides, washed in xylene before being coverslipped with cytoseal. The sections
were viewed with a light microscope (Olympus BX50) and Q-Imaging Retiga 1300 camera
was used to image the silver stained sections.

2.14 Fluorescent microscopy
The Iba-1/EGFP stained brain sections along with the chosen peripheral organ
slides were cover-slipped using hard set mounting media containing DAPI. All brain
sections were viewed on the epifluorescent microscope (Olympus IX50) and imaged at 10X
magnification using a digital camera Q-Imaging Retiga 1300. Only certain areas of the
brain region were imaged due to the large area of the whole brain. In total, eleven areas
were individually acquired from one section of the brain. See Fig. 2 below for the areas that
were imaged. These areas capture the most prominent parts of the brain; superior and lateral
cerebral cortex, corpus callosum, hippocampus, third and lateral ventricles, cerebral
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Figure 2. Areas of the brain that were acquired on the epifluorescent microscope. Each
area labeled A to K were individually imaged at 10x magnification. These areas capture the
most prominent parts of the brain; superior (A&B) and lateral cerebral cortex (D&G), the
third ventricle (C), corpus callosum, hippocampus and lateral ventricles (E&F), cerebral
peduncles and cerebral nuclei (H&I), optic tract and hypothalamus (J&K). The image of
this brain was obtained from Melbourne Brain Center by Dr. Kay L Richards.
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peduncles, optic tract, hypothalamus and cerebral nuclei. The Olympus GFP and RFP filter
cubes were used appropriately to capture EGFP and Iba-1 fluorescent signal, respectively.
All other organs slides including the lungs, livers and spinal cord sections were
viewed and imaged on the EVOS FL Auto 2.0 microscope (Thermo Fisher Scientific). For
each organ, five alternating sections were chosen to be acquired at 10x magnification to
generate images of the entire organ. The 10x tiles were automatically tiled using the EVOS
software. The GFP excitation wavelength of 470 nm and emission wavelength of 510 nm
were used for GFP channel imaging, and 357 nm excitation and 447 nm emission
wavelengths were used for DAPI channel imaging.

2.15 Digital morphometry
All images taken on the Olympus and EVOS fluorescent microscopes were viewed
and the fluorescent signal was quantified using Image Pro Plus 7.0. Tissue sections were
traced to outline the area of interest (AOI), excluding any spaces that are not part of the
tissues, and any morphological abnormalities that were attributed to cryosectioning. Using
manual colour selection, a mask was created to capture Iba-1 or EGFP fluorescent signals.
The same mask was used for the five alternating sections of one organ (lung, liver, spinal
cord). This allows consistency from one section to the next, picking up pixels above the
threshold defined by the mask. Then, the program calculated the “area of EGFP
fluorescence per AOI” and the average of all the five sections from one organ was
generated.
For each brain, five alternate sections 500m apart were selected, stained, and
analyzed. The final Iba-1/EGFP fluorescence was determined by the taking the mean of
individual “area of Iba-1/EGFP fluorescence per AOI” number from the five alternate
sections. For example, the “area of Iba-1/EGFP fluorescence per AOI” number of “area A”
was determined from each of the five alternate sections and those numbers were then
averaged. The same thing was done for all areas A-K. This method of averaging the
immunofluorescence from five alternate sections was used to produce graphs in the
following figures, with the exception of graphs from Fig. 4. Thus, each point on the graph
with the exception from Fig. 4 will represent the average of “A’s, B’s, C’s” etcetera... from
one brain. See Fig. 3 below.
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2.16 Confocal microscopy
Images of microglial, EGFP and CD31 cells at a higher power were acquired on a
Leica-TSC SP8 confocal microscope (Leica Microsystems, Concord, ON) at 63x
magnification. This part of the project was done in conjunction with Dr. Natalie Kozyrev.

2.17 Statistical analysis
Kruskal-Wallis one-way analysis of variance (ANOVA) followed by post-hoc
Dunnett’s tests were performed for the statistical analyses using GraphPad Prism software
version 7.0 (GraphPad Software Inc, La Jolla, CA). Sample size for each group of animals
was between 4 to 10 except for the group of animals used for silver staining, where n=3-4.
Data is presented as a group mean  standard mean of error (SEM). Differences were
considered significant when p<0.05.
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Figure 3. Method of analysis for quantifying brain immunofluorescence. For each brain,
five alternate sections were analyzed. Each “area of fluorescence per AOI” of “area A”
from the five sections were determined individually, then the average immunofluorescence
was calculated. This method was applied to all areas from A to K.
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CHAPTER 3 – RESULTS

3.1 Closed-head injury model of repetitive concussion is a diffuse brain injury
Examining different areas within the same section of the brain and looking at five
different sections within the same brain showed that this model of closed-head, repetitive
concussion is a diffuse brain injury. Five alternate sections from each brain are shown in
Fig. 4A with 0mm being the area directly underneath the bregma. I observed that while
there were differences in the Iba-1 and EGFP immunoreactivity between the time points
(8h, 24h, 48h, 72h, 1w, 2w) compared to controls, there were no spatial differences (+1mm,
+0.5mm, 0mm, -0.5mm, -1mm) in the immunoreactivity within each time point. Thus, the
increase in Iba-1 immunoreactivity at 8h compared to control is relatively constant
regardless of which section is chosen within the same brain. The spatial progression of Iba1 immunoreactivity at each time point in areas A&B and E&F showed no significant
differences between the five sections within each brain (Fig. 4B). The spatial progression
of EGFP immunoreactivity within the same time points in areas A&B and E&F also
showed no significant differences (Fig. 4C). Similarly, areas; C, D&G, H&I, J&K showed
no significant differences between the five alternate sections at any given time point (graphs
not shown). Taken together, the inflammatory response as seen by the increase in Iba-1 and
EGFP immunoreactivity following repetitive mTBI at the indicated time points are
consistent throughout the analyzed brain structure (from +1mm to -1mm). Since the tip of
the impactor is 4mm in diameter, the five sections I have chosen were directly underneath
the area of impact. However, other sections of the brain away from the site of injury should
also be looked at to conclude whether no spatial difference in immunoreactivity exists in
all sections of the brain.

3.2 Increased microglial activation and Iba-1 immunoreactivity in repetitive mTBI brains
To characterize the local CNS-specific inflammatory response following repetitive
concussion in a closed-head injury model, the brains of the mice were removed at 8h, 24h,
48h, 72h, 1w and 2w post-injury, sectioned and doubled stained with Iba-1 and GFP
antibodies. This allows for the distinction of Iba-1+/EGFP- microglia and Iba-1+/EGFP+
hematogenous macrophages and Iba-1-/EGFP+ monocytes and neutrophils. Each area of
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Figure 4. Closed-head, 3 hit model of concussion produces a diffuse brain injury. The five
alternating sections from each brain are shown (A) with 0mm being the area directly
underneath the bregma. The spatial progression of Iba-1 immunoreactivity at each time
point (CNTR, 8h, 24h, 48h, 72h, 1w, 2w) in areas A&B and E&F area shown (B). Similarly,
other areas of the brain including C, D&G, H&I, J&K showed no significant differences
between the five alternate sections (graphs not shown). The spatial progression of EGFP
immunoreactivity at the same points in areas A&B and E&F also showed no significant
differences (C). No significant differences were found between +1mm, +0.5mm, 0mm, 0.5mm and -1mm in all the examined time points. One way ANOVA followed by Dunnett’s
test was performed, significance was determined when *= p<0.05. Data is presented as the
group mean  SEM with 4-5 mice per group.

C)

B)
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Figure 5. Summary of the temporal assessment of Iba-1 immunoreactivity in the control
and repetitive mTBI brains. Quantified Iba-1+ area within the AOI, as determined by digital
morphometry are shown in various areas of the brain at the indicated time points.
Significant increase in Iba-1 immunoreactivity were found at 8h p<0.0001 and 48h
p=0.0015 post-injury in areas containing the superior cerebral cortex (A) as well as the 3rd
ventricle p=0.0064 (B) lateral cortex p<0.0001, p<0.0001 (C), hippocampus and corpus
callosum p<0.0001, p=0.0113 (D), cerebral peduncles nuclei p=0.0015, p=0.0275 (E) and
hypothalamus, optic tract and cerebral nuclei p=0.0052, p<0.0001 (F) all showed the same
pattern of increase in immunoreactivity at 8h and 48h. One way ANOVA followed by
Dunnett’s test was performed, significance was determined when *=p<0.05. Data is
presented as the group mean  SEM with 4-5 mice per group.
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the brain labeled A to K (Fig. 5) were individually imaged and quantified by digital
morphometric analyses. Compared to the controls, animals that sustained three concussive
impacts had significantly higher Iba-1 immunoreactivity, reflective of microglial activation
at 8h and 48h post-concussion for areas A and B which contain regions of the superior
cerebral cortex (Fig. 5A). Examining other areas of the brain, the lateral cortex (Fig. 5C),
hippocampus and corpus callosum (Fig. 5D), cerebral peduncles nuclei (Fig. 5E) and
hypothalamus, optic tract and cerebral nuclei (Fig. 5F) all showed the same pattern of
increase in immunoreactivity at 8h and 48h. The area of Iba-1 immunoreactivity
encompassing the third ventricle and corpus callosum (Fig. 5B) was only significant at 8h.
In all areas, the Iba-1 immunoreactivity returned to baseline levels by 1 week. Although
the data showed no statistical significant increase in Iba-1 immunoreactivity at 24h, there
was still a noticeable increase compared to controls. This may represent a biological
significance, albeit statistically not significant.
Digital brain images representative of the quantitative findings are presented in Fig.
6. Compared to the controls (Fig. 6A, D), the mTBI brains had increased Iba-1
immunoreactivity at 8h (Fig. 6B, D), which returned to control levels by 1 week (Fig. 6C,
F) in both the cerebral cortex and in the corpus callosum. Fluorescent images of Iba-1 at
48h were reflective of that shown at 8h (data not shown). Changes in microglial
morphology were also clearly noticeable. While “resting” and quiescent microglia have a
ramified morphology, activated microglia take on a hypertrophied and bushy appearance.
In the control brains, ramified microglia were observed (Fig. 7A, D) while activated
phenotype was evident at 8h post-injury in both the cortex and corpus callosum in the 3-hit
brains (Fig. 7B, E). Iba-1 immunoreactivity decreased back to control levels at 1 week
following repetitive concussion, although some microglia appeared to remain activated
(Fig. 7C, F).
3.3 Recruitment of EGFP+ myeloid peripheral immune cells into the brain following
repetitive concussion
Using the same double stained sections imaged for Iba-1, temporal assessment of
EGFP immunoreactivity was determined. A significant increase in EGFP immunoreactivity
was not observed until 1 and 2 weeks post-injury in all imaged areas of the brain (areas A-
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Figure 6. Representative images of Iba-1 immunoreactivity in the superior cortex and
corpus callosum. Fluorescent microscopic images of control and mTBI brains at 8h and 1
week post-injury are shown. Panel A shows the superior cortex and panel D shows the
corpus callosum of control brains. Panel B shows the superior cortex and panel E shows
the corpus callosum of mTBI brains at 8h. Panel C shows the superior cortex and panel F
shows the corpus callosum of mTBI brains at 1 week. All images were acquired on the
Olympus IX50 microscope at 10x magnification.
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Figure 7. Representative images of the change in microglial morphology following
repetitive concussive injury. Images of small and ramified microglial morphology from the
control brains in the superior cortex (A) and corpus callosum (D) are shown. Hypertrophied
and busy microglial cells in the superior cortex and corpus callosum in mTBI brains at 8h
(B, E) and 1 week (C, F) are shown. All images were acquired on the confocal microscope
at 63x magnification.
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Figure 8. Summary of the temporal assessment of EGFP immunoreactivity in the control
and mTBI brains. Quantified EGFP+ area within the AOI, as determined by digital
morphometry are shown in various areas of the brain at the indicated time points.
Significant increases in EGFP immunoreactivity were found at 1 week p<0.0001 and 2
weeks p<0.0001 post-injury in areas containing the superior cerebral cortex (A) as well as
the 3rd ventricle p=0.0033, p=0.0108 (B) lateral cortex p<0.0001, p<0.0001(C),
hippocampus and corpus callosum p<0.0001, p=0.0042 (D), cerebral peduncles nuclei
p<0.0001, p<0.0001 (E) and hypothalamus, optic tract and cerebral nuclei p<0.0001,
p<0.0001 (F) all showed the same pattern of increase in immunoreactivity at 1 and 2 weeks.
One way ANOVA followed by Dunnett’s test was performed, significance was determined
when *= p<0.05. Data is presented as the group mean  SEM with 4-5 mice per group.
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Figure 9. Representative images of EGFP immunoreactivity in the superior cortex and
corpus callosum. Fluorescent microscopic images of control and mTBI brains at 8h and 1
week post-injury are shown. Panel A shows the superior cortex and panel D shows the
corpus callosum of control brains. Panel B shows the superior cortex and panel E shows
the corpus callosum of mTBI brains at 8h. Panel C shows the superior cortex and panel F
shows the corpus callosum of mTBI brains at 1 week. All images were acquired on the
Olympus IX50 microscope at 10x magnification.
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K; Fig. 8). Representative immunohistological images showed no difference in EGFP
immunoreactivity at 8h after repetitive concussion (Fig. 9B, E) compared to controls (Fig.
9A, D) but a significant increase was distinctly visible at 1 week post-injury (Fig. 9C, F) in
both the cortex and corpus callosum. Similarly, 2 weeks following repetitive mTBI showed
significant EGFP immunoreactivity compared to controls (data not shown). Additionally,
comparing between the different regions within one brain section, areas A&B, C and J&K
had the highest levels of EGFP immunoreactivity.

3.4 No neutrophils were found in the mTBI brains
There are three predominant types of EGFP+ cells in the lys-EGFP-ki transgenic
mice; neutrophils, monocytes and macrophages. To phenotype these cells and distinguish
them from the brain resident microglial cells, the sections that were double-immunostained
with Iba-1 and EGFP antibodies were observed more closely to see which cells coexpressed or independently expressed Iba-1 and EGFP. As microglia are EGFP-Iba-1+ and
hematogenous macrophages are EGFP+Iba-1+ and hematogenous monocytes and
neutrophils are EGFP+Iba-1-, a merged image of EGFP and Iba-1 showed these phenotypes
(Fig. 10C, F).
To determine if any of the EGFP+ myeloid cells were neutrophils, the brain sections
were stained with a neutrophil marker Ly6G. As the most abundant leukocyte in the
circulation and the first responder to injury and inflammation, neutrophils are known to
extravasate into the brain parenchyma following TBI (148). However, Ly6G staining
showed that very few cells were Ly6G+ (Fig. 11). A stained section of a spleen served as a
positive control (Fig. 11A) to confirm the staining procedure, and another section was
stained without the addition of the primary antibody to show Ly6G specificity (Fig. 11B).
A separate section of a brain from an excitotoxin TBI injury showed Ly6G+ neutrophils
(Fig. 11C), however, in the closed-head repetitive mTBI model, almost no neutrophils were
found in any of the brain regions. Fig. 11D shows the absence of neutrophils in the mTBI
brain at 24h, and this is a representative image for all the time points examined.
3.5 EGFP+ myeloid cells are found in the parenchyma, pia mater, along the choroid plexus
and in the brain microvasculature
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Figure 10. Representative images of EGFP and Iba-1 double immunofluorescence staining
in the cortex of mTBI brains. Superior and lateral cortex areas of mTBI brains at 1 week
showing EGFP immunoreactivity (A, D) Iba-1 immunoreactivity (B, E) and merged images
of EGFP and Iba-1 immunoreactivity (C, F) are shown. Arrow heads indicate whether they
are monocytes or neutrophils, microglia or macrophages. All images were taken on the
confocal microscope at 63x magnification.
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Figure 11. Almost no neutrophils get recruited to the brain following repetitive mTBI.
Spleen was used as a positive control for the staining procedure (A), and the absence of a
primary antibody served as a negative control (B). A separate section of a brain from an
excitotoxin TBI injury showed Ly6G+ neutrophils at 24h (C) while no neutrophils were
found in the closed-head repetitive mTBI brains at 24h (D). All images were acquired on
the EVOS fluorescent microscope at 20x magnification.
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A separate set of brain sections were double-immunostained with antibodies
recognizing EGFP and blood-vessel endothelial marker CD31. This was to determine the
location of the EGFP+ myeloid cells and if these cells emerge from the brain
microvasculature or through the choroid plexus of the lateral ventricles. Fluorescent images
revealed that many larger, phagocytic looking EGFP+ cells were in the brain parenchyma
in the cortex and in the corpus callosum (Fig. 12C, F). However, in the surrounding area,
some smaller EGFP+ cells were found to be co-localized with CD31+ microvessels
indicating the presence of these cells inside the microvasculature (Fig. 12C). Many EGFP+
cells were also found along the edge of the cortex, likely in the pia mater (Fig. 13C, F), but
they did not co-localize with CD31. Lastly, EGFP+ myeloid cells were located along the
choroid plexus within the lateral (Fig. 14C) and 3rd ventricle (Fig. 14F), but again, did not
co-localize with CD31. Altogether, this suggests that the blood-derived myeloid cells
entered the brain through the microvasculature and located in the parenchyma, pia mater
and the ventricles.

3.6 White matter abnormalities found after repetitive concussion
Silver staining is used to observe white matter tract abnormalities based on the idea
that degenerating neurons become argyrophilic, meaning that they have an affinity for
silver. Silver staining was also performed on a separate group of mice (uninjured controls
and those that received 3 closed-head hits; n=3-4 per time point) and sacrificed 72h, 1 and
2 weeks post-injury. The corpus callosum was mainly examined to detect axonal pathology
as this structure is the main white matter tract in the brain. The silver staining data showed
no visual axonal damage in the controls (Fig. 15A) or in the 72h mTBI brains (Fig. 15C).
Additionally, a very small number of EGFP+ cells were found in the corpus callosum (Fig.
15B, D). However, a noticeable increase in axonal injury was evident at 1 and 2 weeks
following repetitive concussion as indicated by strings of small black staining beads (Fig.
15E, G). The presence of EGFP+ myeloid cells was also clearly visible in the corpus
callosum at 1 and 2 weeks after repetitive concussion (Fig. 15F, H).

3.7 Repetitive concussion alters circulating monocyte and neutrophil frequencies in blood
and spleen

54
Figure 12. Representative images of EGFP+ cells that are found in the brain parenchyma.
EGFP+ cells are shown in green (A, D) and endothelial cells of blood vessels are shown in
red (B, E). Merged images of EGFP and CD31 showed EGFP+ cells located in the
microvessels as well as in the parenchyma, indicated by arrow heads (C, F). All images
were taken on the confocal microscope at 63x magnification.
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Figure 13. Representative images of EGFP+ cells that are distributed along in the edge of
the cortex, in the pia mater. EGFP+ cells in the pia mater of superior and lateral cortex are
shown in green (A, D) and endothelial cells of blood vessels are shown in red (B, E) and
merged images of EGFP and CD31 are also shown (C, F). All images were taken on the
confocal microscope at 63x magnification.
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Figure 14. Representative images of EGFP+ cells that are found along the choroid plexus
in the lateral and 3rd ventricles. EGFP+ cells are shown in green (A, D) and endothelial cells
of blood vessels are shown in red (B, E) and merged images of EGFP and CD31 are also
shown (C, F). All images were taken on the confocal microscope at 63x magnification.
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Figure 15. Axonal pathology found in mTBI brains, 1 and 2 weeks following repetitive
concussion. Silver staining was performed on control (A) and repetitive mTBI brains at
72hr (C), 1 week (E) and 2 weeks (G). Adjacent EGFP fluorescent images of areas
surrounding the corpus callosum are shown at the corresponding time points (B, D, F, H).
The rounded black spots in panels A and C show the stained nuclei of the axons. The arrows
in panels E and G indicate the silver varicosities while the arrow heads in panels B, D, F
and H point to the EGFP+ cells in the corpus callosum. Images of silver stained sections
were acquired at 40x magnification on the Olympus BX50 microscope and the fluorescent
images were acquired at 10x magnification by the EVOS microscope.
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To investigate the effects of repetitive concussion on circulating neutrophils and
monocyte subsets, the leukocyte frequencies in peripheral blood and spleen were assessed.
Peripheral whole blood samples and spleens from the control, sham-injured and closedhead 3 hit mice cohorts were stained and analyzed by flow cytometry. Cell populations
were determined using gating strategies for flow cytometry to delineate specific
populations of myeloid cells (Appendix 3). Initial gating selected for, live, single CD45+
hematopoietic lineage cells and negatively selected for myeloid cells by selecting out
CD19+, CD3+, NKp46+ lymphocyte lineage cells. After gating the myeloid cells for
CD11b+Cd11c+ cells, this population was separated based on the expression of F4/80 or
Ly6G. The F4/80+ population was then selected for CD115+ surface expression followed
by Ly6C surface expression. Pro-inflammatory CD11b+F4/80+CD115+Ly6C+/hi and nonclassical monocytes CD11b+F4/80+Ly6Clo/+, while neutrophils are distinguished by
CD11b+F4/80-Ly6G+. EGFP expression was detected in all relevant myeloid subsets, while
EGFP was not detected in the blood-derived lymphocyte subsets of T, B and NK cells. The
graphs show the percentages of each of the cell populations out of the total number of
CD45+ leukocytes. The results showed that in peripheral blood, the classical monocyte
frequency decreased significantly from 8h-1week post-concussion and increased back to
control levels at 2w (Fig. 16A). The non-classical monocytes however, increased slightly
up to 1week before significantly increasing at 2 weeks (Fig. 16B). The trend for neutrophil
frequency was similar to the trend seen in classical monocytes, the neutrophils in
circulation decreased from 8h-1week before significantly increasing at 2 weeks (Fig. 16C).
However, in the spleen, while classical monocytes decreased slightly from 8h to 1week
post-injury (Fig. 16D), non-classical monocytes (Fig. 16E) and neutrophil (Fig. 16F)
frequencies remained at control levels at the same times but also increased after 2 weeks.

3.8 Repetitive concussion causes some changes in the adaptive immune cells in blood and
spleen
To determine the effects of repetitive concussion on circulating lymphocytes, B cell,
T cell and NK cell frequencies in peripheral blood and spleen were assessed. The gating
strategy for the lymphoid panel is shown in Appendix 4. The cells were first gated for the
EGFP- population, followed by single, live CD45+ cells, then CD19+ B cells, and finally
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Figure 16. Innate immune cell frequencies in peripheral blood and spleen following
repetitive concussion. Ly6C+ Classical monocytes, Ly6C- non-classical monocytes and
Ly6G+ neutrophils were identified using flow cytometry. Circulating classical monocyte
frequency were significantly decreased at 8h p=0.0162, 24h p=0.0089, 48h p=0.0141, and
1week p=0.0052 post-injury (A), while non-classical monocytes significantly increased at
2 weeks p=0.0002 (B) and neutrophils were also significantly increased at 2 weeks
p<0.0001 (C). In the spleens, the classical and non-classical monocyte frequencies
significantly increased at 2 weeks p=0.0231, p<0.0001 (D, E). One way ANOVA followed
by Dunnett’s test was performed, significance was determined when *= p<0.05. Data is
presented as the group mean  SEM with 6-10 mice per group.

64

65
Figure 17. Adaptive immune cell frequencies in peripheral blood and spleen. Using flow
cytometry, lymphocyte subsets were identified; B cells as CD19+, T cells as CD3e+ and NK
cells as Nkp46+. Circulating B cells were significantly decreased at 24h p<0.0001 and 48h
p<0.0001 (A), while T cells were found to be significantly increased at 1 week p<0.0001
(B) and NK cells were significantly decreased at 8h p=0.0165 and 72h p<0.0001 (C). In the
spleens, T cells and NK cells were both significantly increased at 2 weeks p=0.0073,
p=0.0043 (E, F). One way ANOVA followed by Dunnett’s test was performed, significance
was determined when *= p<0.05. Data is presented as the group mean  SEM with 6-10
mice per group.
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NKp46+ NK cells and CD3+ T cells. In peripheral blood, B cell frequency significantly
decreased from 24h-48h following TBI (Fig. 17A), while T cells significantly increased at
1 week post-injury (Fig. 17B). In the spleens, T cells and NK cells significantly increased
at 2 week following repetitive concussion (Fig. 17E, F).

3.9 Change in EGFP fluorescence in myeloid cells in the peripheral organs following
repetitive mTBI
To investigate whether repetitive concussion induced a systemic inflammatory
response, livers, lungs and cervical spinal cords were examined for the presence of EGFP+
cells by quantifying the EGFP immunofluorescent signal. These organs were obtained from
the same groups of mice from which the brains, blood and spleens were obtained. Alternate
sections from these organs were imaged using fluorescent microscopy and analyzed using
digital morphometry. The results from livers indicate that while concussion elicited a small
increase in EGFP fluorescent signal, no significant difference between healthy controls and
injured group were found at the indicated time points (8h-2w) (Fig. 18A). Some clusters of
EGFP+ cells were found in both the controls and injured cohorts for all time points (Fig.
18B, C). The results from the lungs revealed that repetitive mTBI lead to a significant
increase in EGFP immunofluorescent signal at 24h (Fig. 19A). However, the EGFP
fluorescence digital signal returned to baseline levels at subsequent time points (48h-2w).
Representative images of lungs from controls and mTBI mice are shown (Fig. 19B, C).
Next, the cervical part of the spinal cords of each animal were analyzed. The cervical region
is the most superior part of the cord, that is directly attached to the brainstem. This area
would likely be the most affected non-brain area from mTBI due to the close, anatomical
proximity to the brain. The results indicated that the 3-hit repetitive brain injury caused
significant accumulation of EGFP+ cells in and surrounding the spinal cords at 8h post-TBI
(Fig. 20A). The EGFP immunofluorescence was greater than a 2-fold increase compared
to healthy controls. This increase was also observed at 24h and 48h, however, to a lesser
extent. At 72h, the EGFP fluorescence returned to control levels and by 2 weeks, it reached
below control levels. Representative images of the spinal cords from controls and injured
cohorts at 8h is shown (Fig. 20B, C).
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Figure 18. No change in EGFP fluorescence of the myeloid cells in the liver following
repetitive mTBI. No significant change in EGFP immunoreactivity was found in the livers
between controls and injured mice cohorts (A). Representative images of the livers are
shown at 10x magnification (B, C). Confocal images of EGFP+ cells (D) acquired at 63x
magnification, along with DAPI (E), and EGFP merged with DAPI (F) are shown. One
way ANOVA followed by Dunnett’s test was performed, significance was determined
when *= p<0.05. Data is presented as the group mean  SEM with 4-5 mice per group. Two
livers from the control and 72h cohorts were omitted from the analysis due to loss of
integrity of the tissue samples.
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Figure 19. EGFP+ fluorescence of myeloid cells increase in the lungs at 24 hours postrepetitive concussion. A significant change in EGFP fluorescent signal was found in the
lungs at 24h in the injured mice cohort p=0.00026 (A). Representative images of the lungs
are shown at 10x magnification (B, C). Confocal images acquired at 63x magnification of
EGFP+ cells (D), along with DAPI (E), and EGFP merged with DAPI (F) are shown. One
way ANOVA followed by Dunnett’s test was performed, significance was determined
when *= p<0.05. Data is presented as the group mean + SEM with 4-6 mice per group.
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Figure 20. EGFP+ fluorescence of myeloid cells increase in the cervical spinal cord at
8hours post-injury. Significant increase in EGFP fluorescent signal was found in the
cervical region of the spinal cord at 8h p<0.0001, 24h p=0.0009, 48h p=0.045 following
repeated mTBI (A). At 2 weeks, the EGFP immunofluorescence decreased significantly
p=0.0015. Representative images of the spinal cords are shown at 10x magnification (B,
C). Close-up confocal images of EGFP+ cells (D), along with DAPI (E), and EGFP merged
with DAPI (F) are shown. One way ANOVA followed by Dunnett’s test was performed,
significance was determined when *= p<0.05. Data is presented as the group mean + SEM
with 4-8 mice per group.

73

74
CHAPTER 4 – DISCUSSION
The overarching goal of this project was to investigate the temporal and spatial
appearance of the local CNS and peripheral immune cells that contribute to the evolving
inflammatory response following repetitive concussion. The closed-head mouse model of
repetitive mTBI generated robust neuroinflammation and some evidence of systemic
inflammation. By using the lys-EGFP-ki transgenic mice, I was able to track the most
prominent inflammatory cells at acute time points following mTBI and distinguish the brain
resident microglia from the hematogenous myeloid cells that extravasate into the brain
parenchyma. Following three concussive impacts, the injured mice exhibited brain
pathologies including significant accumulation of EGFP+ cells in the brain, activated
microglia and white matter abnormalities at sub-acute time points, in the absence of gross
lesions. Furthermore, the injury caused significant increases in EGFP+ cells surrounding
the cervical spinal cord at 8 hours and in the lungs at 24 hours. Altogether, these results
demonstrated that repetitive, mild closed-head injuries produced a robust inflammatory
response in the brain as well as subtle but measurable inflammatory response in the
periphery. This suggests that our model of repetitive concussion is useful for investigating
human concussion and could be further explored to test anti-inflammatory therapies as a
means of providing neuroprotection against secondary injury.
This project investigated the early changes in microglial activity following repeated
concussive injury. The link between multiple concussions and chronic neurodegeneration
has been established in the literature, but, the acute pathological changes following mild
brain injuries need to be further elucidated. Human studies have shown increased microglial
and astrocyte activity through position emission tomography imaging in young NFL
players, which indicate the early onset of neuroinflammation (149). This emphasizes the
importance of understanding the early changes seen in concussion which may help design
future

diagnostic

approaches

and

therapeutics

before

neurodegeneration

and

neurocognitive decline. The results of my research showed that this model of concussive
injury produced key pathological hallmarks of repetitive concussion in the absence of
visible contusions and gross lesions. Just 8 hours following the last injury, there was
significant microglial activity as shown by quantitative analysis, Iba-1 immunoreactivity
was markedly higher in the mTBI brains compared to healthy controls. Whether this is due
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to cell proliferation, increase in cell size or both is unclear and requires clarification with
further experiments. It is known that TBI alters the activation state of microglia which is
characterized by distinct morphological features, including extended processes, amoeboid
and hypertrophied appearance of the cell body (150). Although this does not reflect the
RNA expression profile phenotype, it is still considered as a marker for neuroinflammation
as it indicates that the cells are responding to altered homeostasis. Supported by the Iba-1
staining, mTBI brains had microglia that appeared amoeboid, hypertrophied and bushy
compared to controls which showed ramified morphology associated with normal
surveillance activity. This finding is in accordance with other studies of repetitive
concussion (75).
My data clearly demonstrated the infiltration of hematogenous myeloid cells into
the brain following repetitive mTBI. Examining five different sections (500m apart) of
the brain underneath the site of impact showed that EGFP immunoreactivity remained
consistent between these sections. However, when observing the various areas of the brain
structure within one section, areas near the site of injury (regions encompassing the superior
cerebral cortex) and areas the most ventral from the site of injury (base of the brain) had
the highest levels of EGFP fluorescent signal. I speculate that this could be due to the
“coup-contrecoup” effect. Since the force transmitted by the impactor drives the head and
consequently the brain downward, the coup injury occurred directly underneath where the
impactor made contact with the skull and the contrecoup injury occurred on the opposite
side, which is the most ventral part of the brain. However, the brain is immersed in cerebral
spinal fluid that absorbs the shock from an injury and restricts any significant movement
caused by an external force (151). To further investigate the concept of “coup-contrecoup,”
the exact biomechanical measurements would be required.
The EGFP+ myeloid cells were found in the brain parenchyma, along the choroid
plexus of the lateral and third ventricles, in the pia mater, as well in the microvessels
distributed throughout the parenchyma. Co-localization of EGFP+ and CD31+ cells in the
parenchyma but not in the blood vessels associated with the ventricles or the pia mater
suggests that the myeloid cells emerge from the brain microvasculature and relocate to
other areas. The existence of perivascular, meningeal and choroid plexus macrophages was
previously established in the literature (152). These are non-parenchymal macrophages that
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mediate immune responses at brain boundaries. This explains the presence of EGFP+ cells
in the control brains. However, during neuroinflammatory conditions, the myeloid cells
accumulated significantly more in the parenchyma as well in other areas of the brain.
Additionally, recent research showed the existence of lymphatic vessels in the meninges
that could allow peripheral immune cells to enter and exit the brain as well (153).
It is still controversial as to whether the presence and function of monocyte-derived
macrophages are beneficial or detrimental to recovery following TBI. Traditionally, it was
believed that the recruited peripheral immune cells were more damaging to the brain. Since
the initial wave of infiltrating monocytes involved are likely pro-inflammatory innate
immune cells (154), they are thought to be inherently pathogenic in the context of a sterile
injury such as mTBI. Thus, numerous research efforts have focused on preventing the entry
of monocytes and macrophages by suppressing CCR2 signaling pathway. Reports have
shown that abrogating CCR2-mediated events, thus, impeding monocyte/macrophage
recruitment reduced neuroinflammation and cognitive decline by altering the expression of
pro and anti-inflammatory cytokines (155). Other studies have shown that impaired CCR2
signaling prevented monocyte accumulation and this reduced cavity volume and axonal
pathology following FPI (156). In contrast, some researchers have suggested that peripheral
macrophages enter the CNS to modulate microglial activity and ultimately reduce
inflammation post-TBI (157). This latter in vitro study showed evidence of monocytederived macrophages engaging in cell-to-cell interactions with microglia where infiltrating
macrophages provided ways to mitigate detrimental acute and long-term microglial
mediated inflammation. This occurred through negatively regulating the NF-B signaling
pathway in microglia to reduce inflammatory mediators (157). Further studies are required
to functionally phenotype the hematogenous macrophages in the mTBI brain and this may
shine light on the role that these cells play in the course of TBI resolution or TBI induced
neurodegenerative disease development.
My results showed that in mild concussion-like head injuries, neutrophils were not
the most prominent myeloid cells to infiltrate the brain parenchyma. However, in the
literature, experimental severe TBI lead to the upregulation and release of inflammatory
signals that initiate neutrophil trafficking into the brain (158). Neutrophils are among the
first peripheral immune cells to arrive to the site of lesion, usually within hours after the
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initial impact. They have been shown to extravasate across inflamed vessels, or through the
choroid plexus and circulate in the cerebral spinal fluid near the lesion (158, 159).
Additionally, neutrophils predominately migrate from the brain vasculature to the
ipsilateral leptomeninges and choroid plexus as early as 4 hours after the initial injury and
enter the parenchyma from 24 to 48 hours (160). This is incongruent with my preliminary
results, which showed no neutrophils in the mTBI brains at all examined time points. This
difference could be explained by the much less severe injury in this model of concussion
as opposed to a severe TBI from open-head injury employed in the studies described above.
It is also possible that the neutrophils had already reached and underwent apoptosis after
the first impact. Since the injury was delivered a total of three times and the earliest time
the brains were examined was 8 hours following the last impact, the neutrophils could have
potentially entered and left the brain within those hours. Thus, shorter time points should
also be examined as well as the between the injury intervals.
An important pathological finding that is consistent across the spectrum of TBI
severity (161), as well as in both animal and human studies (162-164) is the selective
damage to axons, known as diffuse axonal injury. While the entire brain suffers from the
mechanical force and the whole brain is susceptible to tissue deformation, white matter
tracts are at the greatest risk of damage due to their direction specific, highly organized
structure (165). The tensile and shear forces from rotational acceleration can damage the
long axonal tracts. TBI causes breaks in the microtubule structures within the axons which
serve as anatomical tracks for protein transport (166). This leads to proteins piling up at the
microtubule disconnections and the evidence of this can be discerned by the appearance of
varicose swelling (164, 166). Although this model of repetitive mTBI induced linear
acceleration, axonal pathology was confirmed in the corpus callosum with silver staining
that specifically reveals the presence of axonal varicosities. DAI is an important secondary
injury marker of repeated concussions that could explain the accelerated path to
neurodegeneration (167-169). Interestingly, EGFP+ cells were also found within the corpus
callosum where there was prominent silver staining axonal varicosities, suggesting a
possible cell-to-cell interaction between the damaged neurons and peripheral myeloid cells.
Although concussion is a CNS injury, the extracranial effects of TBI cannot be
underestimated. In humans, damage to the CNS through acquired TBI can lead to the
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development of a systemic inflammatory response, that may evolve into multiple organ
failure (170). Out of which, lungs are the most affected organ, manifested by ARDS (170).
Pulmonary dysfunction is a critical condition that affects 20-25% of all brain injured
patients and is an important independent factor determining mortality (171). While this is
a more common occurrence in moderate to severe TBI, the effects of mTBI on peripheral
organs is just being elucidated. In this model of repetitive mTBI, a significant accumulation
of EGFP+ myeloid cells 24 hours after injury was shown in the lungs. This is in agreement
with other recent experiments showing significant interstitial neutrophils in a FPI model of
mTBI (172). This latter study demonstrated that concussion primes the lungs for subsequent
neutrophil-mediated injury in a mouse model of mTBI (172). It was shown that mTBI
increased pulmonary susceptibility to secondary injury such as microaspiration of acid
which was mediated by alveolar neutrophil influx that developed into pulmonary
hemorrhage (172).
Additionally, focal brain injuries have shown to elicit a rapid hepatic response
(173). This suggested that the production of chemokines by the liver in response to TBI
acts as an amplifier of the initial inflammatory cascade. In a rat spinal contusion model of
spinal cord injury (SCI), liver inflammation was detected through increased proinflammatory gene expression, increased CD68+ macrophages as well as increased serum
alanine transaminase, which is used to detect liver damage (174). These pathologies
indicated that SCI could produce chronic liver damage with symptoms that resemble those
of nonalcoholic fatty liver disease. Although SCI pathologies differ from that of TBI, SCI
is still an injury inflicted on the CNS that elicits an inflammatory response in the periphery.
No significant changes in EGFP+ myeloid cells were seen in the liver in my experiments at
acute time points, however, repetitive concussion may still induce liver inflammation.
Thus, longer time points post-injury as well as other inflammatory markers should be
investigated.
Interestingly, a significant increase in EGFP+ myeloid cells surrounding the cervical
region of the spinal cord was observed at 8 hours following repetitive concussion. Dr.
Arthur Brown’s lab from Western University, ON, coordinated with engineers also from
Western University to capture a high-speed video of the closed-head injury of concussion
in slow motion. Due to the high-speed impact of the TBI device, at the moment of injury,
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the head of the mouse rapidly accelerates up and down. This could create a strain on the
spinal cord, since the cervical part of the cord directly attaches to the brainstem. This could
potentially explain the accumulation of EGFP+ cells in this region of the spinal cord.
However, conflictingly, DAI and EGFP+ cells increased in the brain at 1 and 2 weeks
following repetitive concussion and not at 8 hours. Additional silver staining of the cervical
spinal cord would be required to determine whether axonal injury correlates with the
accumulation of EGFP+ cells in the spinal cord at 8 hours. This would determine whether
concussion affects both the brain and spinal cord independently of each other regardless of
their anatomical close proximity.
Lastly, an early loss of circulating classical monocytes and neutrophils was
observed at 8 hours which was sustained for a week after the injury. This decrease may be
associated with these cells shifting from the blood into other organs and or brain since there
was an increase in the EGFP+ cells in the lungs and cervical spinal cord. The sudden
increase in the frequencies of these cells at 2 weeks could be explained by the animal
attempting to replenish the initial loss of the EGFP+ cells. Less obvious, yet, similar trends
were seen in the spleen as well, where the classical monocytes and neutrophils slightly
decreased at the earlier time points before increasing at 2 weeks. Importantly, it should be
noted that the results of this study yielded a much lower frequency value of both spleen
monocyte and neutrophil populations. While normal, murine spleen monocyte cell
frequency is reported to be between 3.5-5% and neutrophil frequency is between 4-6% of
total leukocytes (175), frequency values for both in these experiments are 10-fold lower. It
is difficult to speculate the reason for these discrepancies as all cohorts showed the same
lowered values and thus, this part of the project must be redone. Some researchers have
suggested that in an ischemic injury, there exists a separate population of infiltrating
monocytes that originate from the spleen and not from the circulation (176). Hence, it is
believed that the splenic population of monocytes will behave differently from the
monocytes in circulation when activated or recruited to tissues. This is relevant for this
study in that raises the question of where the EGFP+ cells that are found in the organs
originate from and whether their functions differ depending on their origin.
In addition to the myeloid cell populations, 3-hit model of concussion induced some
alterations in the adaptive immune cell populations. While the B cell frequency in

80
circulation decreased from 24 to 48 hours, the T cells remained at control levels until a
striking increase at 1 week. In the literature however, a handful of studies have shown no
changes in the frequency, absolute number, or proliferative capacity of B cells following
severe TBI (177-180). In contrast, severe TBI caused significant decrease in the percentage
and absolute number of T lymphocytes in circulation (178, 181) observed within 24 hours
of injury as well as 4 days. The differences found between my data and what has been
reported in the literature could be explained by the severity of the injury in the concussion
models. Since the role of lymphocytes are not as extensively studied in the TBI literature,
it is difficult to speculate on the changes seen in this model and remains as an area that
needs to be the further explored. Lastly, although the sham-injured cohort was initially
included in the experiments, due to the limited time of this study, the immunohistochemical
results were not completed. A comparison to the sham-injured mice would be necessary to
ensure that the effects of the injury were strictly due to the concussive impacts rather than
from the effects of the anaesthesia and skin incisions.
Possible future directions for this project could be extended from looking beyond
the time points that were examined in my studies. The follow up experiments could
investigate whether the accumulation of EGFP+ cells and axonal injury subside in the brain
and identify the time-point associated with this attenuation. This could clarify the
relationship between peripheral myeloid cells and axonal damage found in the white matter
tracts and help delineate the complex role of myeloid immune cells in the chronic effects
of repetitive mild brain injuries. Additionally, immunohistochemical staining should be
performed to look for gross histological abnormalities. Furthermore, immunostaining brain
sections for a marker of astrocytes with glial fibrillary acidic protein (GFAP) antibody
would also contribute to the overall understanding of the different cell types that play a role
in concussion. Equally as important as the pathological changes, concussion can result in
negative cognitive changes in humans. Thus, behavioural tests should be conducted in
mouse models to determine whether pathological changes correlate with behavioural
changes. An example of such sophisticated behavioural test that could be used is the 5choice serial reaction time test. This is an advanced cognitive testing procedure applicable
to rodents using the touchscreen technology. These tests would model whether the animals
experience decreased mental concentration, slower reaction time by measuring their
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attentional control (182) and cognitive flexibility (183). It is critical to use cognitive testing
that is reflective and relevant to clinical populations. Lastly, sex differences in TBI
pathogenesis should be further explored as there is much evidence to support sexual
dimorphism in the neuroinflammatory response to TBI. Studies have shown that the
inflammatory response in male mice after moderate-CCI differed in comparison to agematched females and exhibited greater myeloid cell infiltration and microglial activation
(184). Along with TBI, Alzheimer’s disease and ischemic stroke injury all lead to sexually
dimorphic outcomes, suggesting sex-related and specific inflammatory signals (185) which
must be accounted for when studying these diseases.
Collectively, my data demonstrated that repetitive, closed-head injury in mice
produces several known pathologies attributed to human concussion including localized,
brain-specific inflammation as well as some evidence of systemic inflammation. Using the
lys-EGFP-ki transgenic mouse model, I characterized the temporal and spatial progression
of the inflammatory process involving the brain resident microglia and monocyte-derived
macrophages in the context of TBI pathology. In addition to neuroinflammation, this model
of concussive injury produced diffuse axonal damage, which is another key hallmark of
concussion. Finally, I concluded that repetitive concussion not only affects the brain, but
also mobilizes the myeloid cells into other organs as well, potentially inducing a cascade
of inflammatory events systemically. Overall, my project sets the stage for further
investigation on the inflammatory response in the CNS and in the periphery. Understanding
the time course of events that lead to these pathologies is critical for the development of
targeted therapies that could impede the progression towards potential long-term
impairments.
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Appendix

Appendix 1. Animal ethics approval.
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Appendix 2. The Iba-1 antibody specificity. Panel A and B show different areas of the
brain that are not Iba-1+ due to the lack of primary Iba-1 antibody. Panel C and D show Iba1+ staining in different brain regions when the primary Iba-1 antibody is added. This
confirms the specificity of the Iba-1 antibody.

A)

B)

C)

D)
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Appendix 3. Optimized gating strategy for identifying myeloid lineage cell populations in
both blood and spleen via flow cytometry. First, the counting beads were separated from
the cell scatter, then viable and single cells were selected. Myeloid cells were gated for
CD45+CD11b+ and discriminated against CD19+, CD3+ and NKp46+ cells. Classical
monocytes were identified as F4/80+CD115+Ly6C+GFP+, non-classical monocytes as
F4/80+CD115+Ly6C-GFP+ and neutrophils are Ly6G+GFP+.
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Appendix 4. Optimized gating strategy for identifying lymphoid lineage cell populations
in both blood and spleen via flow cytometry. First, the counting beads were separated from
the cell scatter, then EGFP+ myeloid cell populations were gated out to select for lymphoid
cells. After viable cells, singlets and CD45+ cell population were selected, T cells were
identified by EGPF-CD45+CD3+, B cells as EGFP-CD45+CD19+, NK cells as EGFPCD45+NKp46+.
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